Terms: = Ovarian cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Diagnosis
13 results:
1. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
Dos Santos MV; Holth A; Bischof K; Davidson B
Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of American College of Radiology ovarian-Adnexal Reporting and Data System ultrasound to predict malignancy risk in adnexal lesions.
Li Y; Shao G; Wu M; Zhang F; Zhang Y; Shao C
J Obstet Gynaecol Res; 2024 Feb; 50(2):225-232. PubMed ID: 37990446
[TBL] [Abstract] [Full Text] [Related]
3. Germline Genetic Testing After cancer diagnosis.
Kurian AW; Abrahamse P; Furgal A; Ward KC; Hamilton AS; Hodan R; Tocco R; Liu L; Berek JS; Hoang L; Yussuf A; Susswein L; Esplin ED; Slavin TP; Gomez SL; Hofer TP; Katz SJ
JAMA; 2023 Jul; 330(1):43-51. PubMed ID: 37276540
[TBL] [Abstract] [Full Text] [Related]
4. Reproductive Outcomes in Young Breast cancer Survivors Treated (15-39) in Ontario, Canada.
Rushton M; Pudwell J; Wei X; Powell M; Richardson H; Velez MP
Curr Oncol; 2022 Nov; 29(11):8591-8599. PubMed ID: 36421330
[TBL] [Abstract] [Full Text] [Related]
5. Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study.
Gao Y; Zeng S; Xu X; Li H; Yao S; Song K; Li X; Chen L; Tang J; Xing H; Yu Z; Zhang Q; Zeng S; Yi C; Xie H; Xiong X; Cai G; Wang Z; Wu Y; Chi J; Jiao X; Qin Y; Mao X; Chen Y; Jin X; Mo Q; Chen P; Huang Y; Shi Y; Wang J; Zhou Y; Ding S; Zhu S; Liu X; Dong X; Cheng L; Zhu L; Cheng H; Cha L; Hao Y; Jin C; Zhang L; Zhou P; Sun M; Xu Q; Chen K; Gao Z; Zhang X; Ma Y; Liu Y; Xiao L; Xu L; Peng L; Hao Z; Yang M; Wang Y; Ou H; Jia Y; Tian L; Zhang W; Jin P; Tian X; Huang L; Wang Z; Liu J; Fang T; Yan D; Cao H; Ma J; Li X; Zheng X; Lou H; Song C; Li R; Wang S; Li W; Zheng X; Chen J; Li G; Chen R; Xu C; Yu R; Wang J; Xu S; Kong B; Xie X; Ma D; Gao Q
Lancet Digit Health; 2022 Mar; 4(3):e179-e187. PubMed ID: 35216752
[TBL] [Abstract] [Full Text] [Related]
6. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
[TBL] [Abstract] [Full Text] [Related]
7. ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
Derks-Smeets IAP; Schrijver LH; de Die-Smulders CEM; Tjan-Heijnen VCG; van Golde RJT; Smits LJ; Caanen B; van Asperen CJ; Ausems M; Collée M; van Engelen K; Kets CM; van der Kolk L; Oosterwijk JC; van Os TAM; ; Rookus MA; van Leeuwen FE; Gómez García EB
Br J Cancer; 2018 May; 119(3):357-363. PubMed ID: 29937543
[TBL] [Abstract] [Full Text] [Related]
8. Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous ovarian cancer Cytoreduction Surgery.
Spencer RJ; Hacker KE; Griggs JJ; Rice LW; Reynolds RK; Uppal S
Obstet Gynecol; 2017 Aug; 130(2):305-314. PubMed ID: 28697111
[TBL] [Abstract] [Full Text] [Related]
9. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
10. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study.
Macuks R; Baidekalna I; Donina S
Asian Pac J Cancer Prev; 2012; 13(9):4695-8. PubMed ID: 23167404
[TBL] [Abstract] [Full Text] [Related]
11. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis.
Vay A; Kumar S; Seward S; Semaan A; Schiffer CA; Munkarah AR; Morris RT
Gynecol Oncol; 2011 Dec; 123(3):456-60. PubMed ID: 21855120
[TBL] [Abstract] [Full Text] [Related]
12. [Studies of clinical usefulness of new tumor markers of ovarian cancer, CA 54/61 and CA 602--CA 602 assay reagent kit, performance its normal value and correlations with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2085-93. PubMed ID: 1417016
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
Ito K; Udagawa Y; Nozawa S
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
[TBL] [Abstract] [Full Text] [Related]
